Relationship Between Steatosis, Inflammation, and Fibrosis in Chronic Hepatitis C: A Meta-Analysis of Individual Patient Data

Leandro, Gioacchino; Mangia, Alessandra; Hui, Jason M.; Fabris, Paolo; Rubbia‐Brandt, Laura; Colloredo, Guido; Adinolfi, Luigi Elio; Asselah, Tarik; Jonsson, Julie R.; Smedile, Antonina; Terrault, Norah A.; Pazienza, Valerio; Giordani, Maria Teresa; Giostra, Emiliano; Sonzogni, Aurelio; Ruggiero, Giuseppe; Marcellin, Patrick; Powell, Elizabeth E.; George, Jacob; Negro, Francesco

doi:10.1053/j.gastro.2006.03.014

Cited by 508 publications

(425 citation statements)

References 35 publications

Supporting

Mentioning

383

Contrasting

Unclassified

Order By: Relevance

“…168 Coexistent hepatic steatosis is common in chronic hepatitis C (HCV) infection and is strongly associated with more advanced liver disease. [169][170][171] Another large study showed high prevalence of steatosis (40.5%) and steatohepatitis (15%) in patients with primary biliary cirrhosis (PBC), 172 although at least some of the steatosis and steatohepatitis in that study was suspected to be due to alcohol consumption. In clinical practice, it is not uncommon for obese and/or diabetic patients with autoimmune liver disease to exhibit steatosis and steatohepatitis in their liver biopsies.…”

Section: Bariatric Surgerymentioning

confidence: 97%

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

et al. 2012

View full text Add to dashboard Cite

Section: Bariatric Surgerymentioning

confidence: 97%

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

et al. 2012

View full text Add to dashboard Cite

“…The need for a liver biopsy to initiate and monitor the treatment is the main hurdle to this objective at the present time. The development of reliable surrogate markers of fibrosis in the future may solve this problem [52].…”

Section: Therapy Of Liver Fibrosismentioning

confidence: 99%

Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL)

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Current estimations find that more than one-fourth of HIV-infected patients are coinfected with HCV, 1 and HCV-related deaths are now the third cause of death in HIVinfected patients. 2 When compared to the general population, HCVinfected patients have a 2.5-fold increased risk of developing hepatic steatosis (HS), 3 often associated with faster fibrosis progression and more severe hepatic fibrosis, 4 an increased risk of hepatocellular carcinoma development, 5 and lower rates of sustained viral response to HCV antiviral therapy, mainly in genotype 3. 6 There are two types of HS in HCV infection, a viral-related HS and a metabolic-related HS.…”

mentioning

confidence: 99%

Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: A meta-analysis of the risk factors

2010

View full text Add to dashboard Cite

Hepatic steatosis (HS) is frequent in patients with hepatitis C virus (HCV) infection, occurring in 40%-80%, associating with metabolic and virus-related factors, namely, genotype 3 and viral load. Human immunodeficiency virus (HIV) infection and antiretroviral treatment seem to be risk factors for HS. Several studies addressed this issue in coinfected patients, with discrepant results. A meta-analysis was performed on the HS risk factors in coinfected patients. Eligible studies were identified through structured keywords including coinfection, HCV, HIV, and steatosis in relevant databases including PubMed. Pooled odds ratios (ORs) and confidence limits (CIs) were obtained with the random-effects model and the DerSimonian-Laird method. Twelve studies, including 1,989 coinfected patients, were selected. Twenty percent were infected with HCV genotype 3. The overall prevalence of HS was 50.8% (23%-72%). Four studies also included 1,540 HCV monoinfected patients, not showing an increased risk for HS in coinfected patients (OR 1.61, 95% CI 0.84-3.10, P 5 0.151). In coinfected patients, HS was associated with higher body mass index (OR 1.13, 95% CI 1.07-1.19, P < 0.001), diabetes mellitus (OR 2.32, 95% CI 1.32-4.07, P 5 0.003), elevated alanine aminotransferase levels (OR 1.28, 95% CI 1.02-1.61, P 5 0.035), necroinflammatory activity (OR 1.72, 95% CI 1.11-2.67, P 5 0.016), and fibrosis (OR 1.67, 95% CI 1.20-2.34, P 5 0.003). No associations were found between HS and gender, other metabolic factors (dyslipidemia, glucose, metabolic syndrome), HCV-related factors (genotype, viral load), or HIV-related factors (viral load, CD4 count, antiretroviral therapy, and class of medication). Conclusion: In coinfected patients, HS does not seem to be more frequent than in HCV monoinfected patients and is mostly associated with metabolic factors, such as increased weight, diabetes mellitus, and more severe liver disease. The fact that no associations with HCV factors were found may be due to the small percentage of genotype 3-infected patients. (HEPATOLOGY 2010;52:71-78)

show abstract

Relationship Between Steatosis, Inflammation, and Fibrosis in Chronic Hepatitis C: A Meta-Analysis of Individual Patient Data

Cited by 508 publications

References 35 publications

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL)

Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: A meta-analysis of the risk factors

Contact Info

Product

Resources

About